(CRRX) CareRx - Ratings and Ratios
Exchange: TO • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA14173C1059
CRRX: Medication, Management, Technology, Pharmacy, Solutions
CareRx Corporation (TO:CRRX) operates as a provider of pharmacy services tailored to senior living communities and congregate care settings across Canada. The company specializes in medication management solutions, integrating technology and programmatic offerings to optimize care delivery. Its client base includes long-term care facilities, retirement homes, assisted living centers, and group homes. Originally established as Centric Health Corporation in 2001, the company rebranded to CareRx Corporation in June 2020. Headquartered in Toronto, Canada, CareRx focuses on enhancing medication adherence and streamlining healthcare operations for its clients.
3-Month Forecast: Based on
Additional Sources for CRRX Stock
CRRX Stock Overview
Market Cap in USD | 116m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception |
CRRX Stock Ratings
Growth 5y | -33.1% |
Fundamental | 38.1% |
Dividend | 0.0% |
Rel. Strength | 35.1 |
Analysts | - |
Fair Price Momentum | 2.55 CAD |
Fair Price DCF | 9.88 CAD |
CRRX Dividends
No Dividends PaidCRRX Growth Ratios
Growth Correlation 3m | 72% |
Growth Correlation 12m | 20.5% |
Growth Correlation 5y | -77.7% |
CAGR 5y | -6.97% |
CAGR/Max DD 5y | -0.08 |
Sharpe Ratio 12m | -0.11 |
Alpha | 27.31 |
Beta | 0.823 |
Volatility | 35.64% |
Current Volume | 22.2k |
Average Volume 20d | 7.3k |
As of April 08, 2025, the stock is trading at CAD 2.65 with a total of 22,200 shares traded.
Over the past week, the price has changed by -1.49%, over one month by +3.92%, over three months by +23.26% and over the past year by +29.27%.
Partly, yes. Based on ValueRay Fundamental Analyses, CareRx (TO:CRRX) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 38.14 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRRX as of April 2025 is 2.55. This means that CRRX is currently overvalued and has a potential downside of -3.77%.
CareRx has no consensus analysts rating.
According to ValueRays Forecast Model, CRRX CareRx will be worth about 2.8 in April 2026. The stock is currently trading at 2.65. This means that the stock has a potential upside of +6.04%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3.7 | 40.8% |
Analysts Target Price | - | - |
ValueRay Target Price | 2.8 | 6% |